Lakeside Revenue Jumps 49% on Pharma Push, Net Loss Widens

TL;DR

**LSH is growing revenue fast with its pharma bet, but the widening losses and cash burn mean it's a speculative play.**

AI Summary

Lakeside Holding Ltd (LSH) reported a significant increase in total revenue to $6,099,889 for the three months ended September 30, 2025, up 49.44% from $4,081,554 in the same period of 2024. This growth was primarily driven by the new revenue stream from the distribution of pharmaceutical products, which contributed $1,338,015, and a 16.17% increase in cross-border freight solutions revenue from third parties to $4,181,714. Despite the revenue growth, the company's net loss widened slightly to $1,357,216 from $1,335,407 year-over-year. Gross profit more than doubled to $1,108,767 from $522,539, but operating expenses surged to $2,380,391, including $189,411 in selling expenses and a significant increase in general and administrative expenses to $2,107,655. Cash decreased by $416,424 to $4,539,636, primarily due to $4,016,518 in cash used in operating activities, partially offset by $3,672,316 from financing activities, including a $3,000,000 private placement and $1,916,200 in common stock issued for consulting services.

Why It Matters

Lakeside's aggressive expansion into pharmaceutical distribution, evidenced by $1.34 million in new revenue, signals a strategic pivot that could diversify its business beyond freight. However, the widening net loss and substantial increase in operating expenses, particularly general and administrative costs, raise questions about profitability and operational efficiency. For investors, this mixed performance suggests a high-growth, high-risk profile, as the company is burning cash in operations. Competitively, this move into pharma could position Lakeside against established distributors, but its ability to scale profitably remains unproven.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,357,216 for the quarter and used $4,016,518 in cash from operating activities. This significant cash burn, coupled with a decrease in cash from $4,956,060 to $4,539,636, indicates ongoing liquidity challenges and a reliance on financing activities, such as the $3,000,000 private placement, to sustain operations.

Analyst Insight

Investors should monitor Lakeside Holding Ltd's next few quarters closely for signs of improved operational efficiency and a path to profitability in its new pharmaceutical segment. Given the high cash burn and widening net loss, a 'wait and see' approach is advisable, focusing on whether the new revenue streams can translate into positive operating cash flow.

Financial Highlights

debt To Equity

N/A

revenue

$6,099,889

operating Margin

-20.99%

total Assets

$18,635,189

total Debt

N/A

net Income

-$1,357,216

eps

-$0.09

gross Margin

18.18%

cash Position

$4,539,636

revenue Growth

+49.44%

Revenue Breakdown

Key Numbers

• $6,099,889 — Total Revenue (Increased by 49.44% from $4,081,554 year-over-year, driven by new pharma distribution.)
• $1,338,015 — Revenue from pharmaceutical products (New revenue stream for the three months ended September 30, 2025.)
• $1,357,216 — Net Loss (Widened from $1,335,407 in the prior year period.)
• $1,108,767 — Gross Profit (More than doubled from $522,539 in the prior year period.)
• $2,380,391 — Total Operating Expenses (Increased significantly from $1,850,043 in the prior year period.)
• $4,016,518 — Net Cash Used in Operating Activities (Increased from $1,402,784 in the prior year period, indicating higher cash burn.)
• $4,539,636 — Cash, end of period (Decreased from $4,956,060 at the beginning of the period.)
• $3,000,000 — Proceeds from a private placement (Significant financing activity during the quarter.)
• 17,427,559 — Common Stock Outstanding (Increased from 10,500,000 shares as of June 30, 2025.)
• $1,916,200 — Common stock issued for consulting services (Non-cash financing activity during the quarter.)

Key Players & Entities

• Lakeside Holding Limited (company) — registrant
• Nasdaq Capital Market (regulator) — stock exchange
• Henry Liu (person) — Chief Executive Officer
• Shuai Li (person) — President
• American Bear Logistics Corp. (company) — subsidiary providing logistics services
• Hupan Pharmaceutical (Hubei) Co., Ltd (company) — subsidiary for pharmaceutical distribution
• Federal Deposit Insurance Corporation (regulator) — US bank insurer
• People's Bank of China Financial Stability Department (regulator) — China bank insurer

FAQ

Risk Factors

• Widening Net Loss Despite Revenue Growth [medium — financial]: The company's net loss widened to $1,357,216 from $1,335,407 year-over-year, despite a 49.44% increase in total revenue. This indicates that the cost of generating this new revenue, particularly from pharmaceutical distribution and increased operating expenses, is outpacing the revenue gains.
• Significant Increase in Operating Expenses [medium — operational]: Total operating expenses surged by 28.66% to $2,380,391 from $1,850,043 in the prior year period. This increase is largely driven by a substantial rise in general and administrative expenses to $2,107,655, which grew by 14.7% year-over-year, and the introduction of selling expenses ($189,411) not present in the prior year.
• Increased Cash Burn from Operations [high — financial]: Net cash used in operating activities increased dramatically by 186.31% to $4,016,518 from $1,402,784 in the prior year period. This significant increase in cash burn is a concern for liquidity, even with recent financing activities.
• Dilution from Stock Issuances [medium — financial]: The company issued 2,300,000 shares for consulting services and 3,807,229 shares in a private placement, significantly increasing the common stock outstanding from 10,500,000 to 17,427,559. This dilutes existing shareholders' equity and earnings per share.
• Pharmaceutical Distribution Compliance [medium — regulatory]: The new revenue stream from pharmaceutical product distribution introduces regulatory compliance risks specific to the pharmaceutical industry. Failure to adhere to regulations could lead to penalties, reputational damage, and disruption of this key growth area.
• Dependence on Financing Activities [high — financial]: The company relied heavily on financing activities, including a $3,000,000 private placement and $1,916,200 in stock issued for services, to partially offset its operating cash burn. This reliance on external funding, especially equity, can be unsustainable if operational profitability does not improve.

Industry Context

Lakeside Holding Ltd operates in the logistics and freight solutions sector, which is highly competitive and sensitive to global trade volumes and economic conditions. The recent expansion into pharmaceutical distribution introduces it to a highly regulated and specialized market. Key trends include increasing demand for efficient cross-border logistics, the growing importance of supply chain resilience, and the digitalization of freight services. The pharmaceutical sector requires stringent adherence to quality control and distribution regulations.

Regulatory Implications

The company faces standard regulatory requirements for logistics operations, including customs, transportation, and safety regulations. The new pharmaceutical distribution business subjects LSH to specific healthcare and pharmaceutical regulations, such as those governing the handling, storage, and transport of medicines. Compliance failures in either sector could lead to significant fines, operational disruptions, and reputational damage.

What Investors Should Do

1. Monitor operating expense control
2. Analyze the profitability of the pharmaceutical segment
3. Assess cash burn and future financing needs
4. Evaluate the impact of share dilution

Key Dates

• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing significant revenue growth but a widening net loss and increased operating expenses.
• 2025-07-01: IPO Date (mentioned in notes) — Company began trading on Nasdaq Capital Market, marking a transition to a publicly traded entity.
• 2024-11-21: Hupan Pharmaceutical (Hubei) Co., Ltd established — Establishment of the subsidiary focused on pharmaceutical distribution, the new key revenue driver.
• 2024-07-10: Sichuan Hupan Jincheng Enterprise Management Co., Ltd acquired — Expansion into China to explore business opportunities.
• 2024-03-29: 120-for-1 share split — Adjusted share structure prior to IPO.

Glossary

Right of return asset

An asset recognized when a seller allows customers to return goods, representing the expected value of those returns. (Indicates potential future revenue reversals or costs associated with product returns, impacting net sales and inventory valuation.)

Contract assets

Represents the entity's right to consideration in exchange for performance obligations that have been transferred to a customer. It arises when the entity has performed but is not yet unconditionally entitled to payment. (Reflects revenue recognized but not yet billed, important for understanding the timing of cash flows and revenue recognition.)

Provision of allowance for expected credit loss

An accounting estimate for potential losses on accounts receivable that are not expected to be collected. (Shows the company's assessment of credit risk in its receivables, impacting reported asset values and operating expenses.)

Stock-based compensation expense for consulting services

The cost recognized for equity instruments granted to non-employees (consultants) in exchange for services, valued at the fair value of the instruments. (Represents a non-cash expense that dilutes equity and impacts net income, reflecting the cost of acquiring services through equity.)

Weighted Average Shares Outstanding

The average number of outstanding shares over a period, adjusted for the timing and number of shares issued or repurchased. (Crucial for calculating Earnings Per Share (EPS), showing the impact of share issuances on per-share metrics.)

Year-Over-Year Comparison

Compared to the prior year period, Lakeside Holding Ltd has demonstrated impressive revenue growth of 49.44%, largely fueled by a new pharmaceutical distribution segment. However, this top-line expansion has not translated into improved profitability, as the net loss widened slightly. Gross profit more than doubled, indicating improved efficiency in cost of revenue relative to sales, but this was overshadowed by a significant 28.66% increase in operating expenses, particularly in general and administrative costs. The company's cash position decreased due to a substantial rise in operating cash burn, necessitating significant financing activities, including a private placement and stock issuance for services, which led to considerable share dilution.

Key Financial Figures

• $0.0001 — h Registered Common Stock, par value US$0.0001 per share LSH The Nasdaq Stock Market L

Filing Documents

• ea0265749-10q_lakeside.htm (10-Q) — 1225KB
• ea026574901ex31-1_lakeside.htm (EX-31.1) — 9KB
• ea026574901ex31-2_lakeside.htm (EX-31.2) — 10KB
• ea026574901ex32-1_lakeside.htm (EX-32.1) — 3KB
• ea026574901ex32-2_lakeside.htm (EX-32.2) — 4KB
• 0001213900-25-112601.txt ( ) — 9332KB
• lsh-20250930.xsd (EX-101.SCH) — 90KB
• lsh-20250930_cal.xml (EX-101.CAL) — 86KB
• lsh-20250930_def.xml (EX-101.DEF) — 465KB
• lsh-20250930_lab.xml (EX-101.LAB) — 777KB
• lsh-20250930_pre.xml (EX-101.PRE) — 490KB
• ea0265749-10q_lakeside_htm.xml (XML) — 1149KB

Signatures

Signatures 17 i EXPLANATORY NOTE As used in this Quarterly Report on Form 10-Q, unless otherwise indicated or the context otherwise requires, references to "Lakeside," "the Company," "we," "us," and "our" refer to Lakeside Holding Limited together with its consolidated subsidiaries. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This report contains certain are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent management's expectations or forecasts of future events. Forward-looking statements are typically identified by words such as "anticipate," "believe," "estimate," "expect," "forecast," "project," "intend," "plan," "probably," "potential," "looking forward," "continue," and other similar terms, and future or conditional tense verbs like "could," "may," "might," "should," "will," and "would." You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from either historical or anticipated results depending on a variety of factors. Forward-looking statements in this Form 10-Q may include, for example, statements concerning: our future operating and financial performance, ability to generate positive cash flow and ability to achieve and sustain profitability; our competitive position; the sufficiency of our existing capital resources to fund our future operating expenses; the timing of the introduction of new solutions and services; the likelihood of success in and impact of litigation; our protection or enforcement of our intellectual property rights; our expectation with respect to securities, options and future ma

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and June 30, 2025 F-2 Condensed Consolidated F-3 Condensed Consolidated F-4 Condensed Consolidated F-5 Notes to Condensed Consolidated Financial Statements (unaudited) F-6 – F-45 F-1 LAKESIDE HOLDING LIMITED CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2025 (UNAUDITED) AND JUNE 30, 2025 As of September 30, 2025 (unaudited) As of June 30, 2025 ASSETS CURRENT ASSETS Cash $ 4,539,636 $ 4,956,060 Accounts receivable – third parties, net of credit loss allowance of $ 171,613 and $ 87,728 3,091,279 2,895,580 Accounts receivable – related party, net of credit loss allowance of $ nil and $ nil 352,896 396,331 Note receivable 13,873 65,152 Prepayment, deposit and other receivable – third parties 4,948,382 449,977 Other receivable – related party 1,146,844 869,430 Contract assets 49,392 119,054 Inventories, net 131,986 96,534 Right of return asset 80,554 141,687 Loan receivable from related parties 386,541 277,741 Loan receivable from a third party 253,107 11,380 Total current assets 14,994,490 10,278,926 NON-CURRENT ASSETS Long- term investment 15,741 15,741 Property and equipment at cost, net of accumulated depreciation 409,393 389,421 Intangible assets, net 344,069 365,440 Right of use operating lease assets 2,687,972 3,158,202 Right of use financing lease assets 85,197 93,797 Deposit and prepayment 98,327 103,934 Total non-current assets 3,640,699 4,126,535 TOTAL ASSETS $ 18,635,189 $ 14,405,461 LIABILITIES AND EQUITY CU

financial statements (unaudited)

financial statements (unaudited). F-2 LAKESIDE HOLDING LIMITED CONDENSED CONSOLIDATED STATEMENT OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) For The Three Months Ended September 30, 2025 2024 Revenue from cross-border freight solutions – third party $ 4,181,714 $ 3,599,787 Revenue from cross-border freight solutions – related parties 580,160 481,767 Revenue from distribution of pharmaceutical products – third parties 1,338,015 - Total revenue 6,099,889 4,081,554 Cost of revenue from cross-border freight solutions – third party 3,733,846 2,994,285 Cost of revenue from cross-border freight solutions – related party 466,506 564,730 Cost of revenue from pharmaceutical products – third parties 790,770 - Total cost of revenue 4,991,122 3,559,015 Gross profit 1,108,767 522,539 Operating expenses: Selling expenses 189,411 - General and administrative expenses 2,107,655 1,837,206 Provision of allowance for expected credit loss 83,325 12,837 Total operating expenses 2,380,391 1,850,043 Loss from operations ( 1,271,624 ) ( 1,327,504 ) Other income (expense) Other income, net 146,839 109,788 Interest expense ( 196,441 ) ( 28,110 ) Total other (expense) income ( 49,602 ) 81,678 Loss before income taxes ( 1,321,226 ) ( 1,245,826 ) Income tax expense 35,990 89,581 Net loss ( 1,357,216 ) ( 1,335,407 ) Other comprehensive (loss) income: Foreign currency translation gain 36,928 12,993 Comprehensive loss $ ( 1,320,288 ) $ ( 1,322,414 ) Loss per share – basic and diluted $ ( 0.09 ) $ ( 0.18 ) Weighted Average Shares Outstanding – basic and diluted 14,733,489 7,500,000 The accompanying notes are an integral part of these condensed consolidated

financial statements (unaudited)

financial statements (unaudited). F-3 LAKESIDE HOLDING LIMITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) Common Shares Amount Subscription Receivable Additional Paid in Capital Deficits Accumulated Other Comprehensive Income Total Balance at June 30, 2024 6,000,000 $ 600 $ ( 600 ) $ 642,639 $ ( 5,819 ) $ 2,972 $ 639,792 Paid in capital — — 600 — — — 600 Net loss for the three months ended September 30, 2024 — — — — ( 1,335,407 ) — ( 1,335,407 ) Initial public offering, net of share issuance costs 1,500,000 150 — 4,300,152 — — 4,300,302 Foreign currency translation adjustment — — — — — 12,993 12,993 Balance at September 30, 2024 7,500,000 $ 750 $ — $ 4,942,791 $ ( 1,341,226 ) $ 15,965 $ 3,618,280 Common Shares Amount Additional Paid in Capital Deficits Accumulated Other Comprehensive Income Statutory Reserves Total Balance at June 30, 2025 10,500,000 $ 1,050 $ 8,084,275 $ ( 5,315,371 ) $ 12,315 $ 63,416 $ 2,845,685 Net loss for the three months ended September 30, 2025 — — — ( 1,357,216 ) — — ( 1,357,216 ) Statutory reserve — — — ( 11,192 ) — 11,192 — Foreign currency translation gain — — — — 36,928 — 36,928 Common stock issued for consulting services 2,300,000 230 1,915,970 — — — 1,916,200 Issuance of common shares upon exercise of Convertible note 820,330 82 512,651 — — — 512,733 Issuance of common shares - Private placement 3,807,229 381 2,999,619 — — — 3,000,000 Balance at September 30, 2025 17,427,559 $ 1,743 $ 13,512,515 $ ( 6,683,779 ) $ 49,243 $ 74,608 $ 6,954,330 The accompanying notes are an integral part of these condensed consolidated

financial statements (unaudited)

financial statements (unaudited). F-4 LAKESIDE HOLDING LIMITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE PERIOD ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) For the Three Months Ended September 30, 2025 2024 Cash flows from operating activities: Net loss $ ( 1,357,216 ) $ ( 1,335,407 ) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation – G&A 25,898 17,995 Depreciation – cost of revenue 24,667 18,164 Amortization of intangible asset 21,371 — Straight line lease expense of operating leases 527,261 466,723 Depreciation of right-of-use finance assets 8,600 7,595 Amortization of discount and bond issuance cost 69,602 — Provision of allowance for expected credit loss 83,325 12,837 Deferred tax expense ( 21,989 ) 89,581 Interest income ( 60,561 ) — Stock-based compensation expense for consulting services 359,239 — Changes in operating assets and liabilities: Accounts receivable – third parties ( 279,024 ) 282,864 Accounts receivable – related parties 43,435 257,924 Note receivable 51,279 — Contract assets 69,662 88,205 Inventories, net ( 35,452 ) — Right of return assets 61,133 — Other receivable – related parties ( 82,118 ) ( 77,812 ) Prepayment, deposit and other receivable – third parties ( 2,935,837 ) ( 176,572 ) Accounts payables – third parties 45,114 ( 402,895 ) Accounts payables – related parties 39,445 ( 156,850 ) Contract liabilities 18,175 — Accrued expense and other payables 37,887 (24,876 Refund liabilities 121,571 — Tax payable 45,704 — Operating lease liabilities ( 897,689 ) ( 470,260 ) Net cash used in operating activities ( 4,016,518 ) ( 1,402,784 ) Cash flows from investing activities: Purchase of property and equipment — ( 5,772 ) Prepayment for system installation — ( 32,507 ) Loan to related parties ( 108,800 ) — Net cash used in investing activities ( 108,800 ) (

financial statements (unaudited)

financial statements (unaudited). F-5 LAKESIDE HOLDING LIMITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION Lakeside Holding Limited (the "Company"), is a holding company established on August 28, 2023 under the laws of the State of Nevada. The Company, acting through its subsidiary, is primarily engaged in providing customized cross-border ocean freight solutions and airfreight solutions. On July 1, 2024, the Company closed its initial public offering ("IPO") of 1,500,000 shares of its common stock at an IPO price of $ 4.50 per share for aggregate gross proceeds of approximately $ 6.75 million from the offering (Note 17). In connection with the offering, the Company's common shares began trading on the Nasdaq Capital Market under the trading symbol "LSH." As of September 30, 2025, the Company's subsidiaries are as follows: Name Date of Incorporation/ Acquisition Jurisdiction of Formation Percentage of direct/indirect Economic Activities Parent Company Lakeside Holding Limited August 28, 2023 Nevada Parent Holding company Subsidiaries/companies with ownership American Bear Logistics Corp. ("ABL Chicago") February 5, 2018 Illinois 100 % Logistics services Sichuan Hupan Jincheng Enterprise Management Co., Ltd ("Sichuan Hupan") July 10, 2024 Sichuan, China 100 % Exploring business opportunities in China Hupan Pharmaceutical (Hubei) Co., Ltd ("Hupan Pharmaceutical") November 21, 2024 Hubei, China 100 % Medical injection and pharmaceutical distributor Reorganization A reorganization of the legal structure was completed on September 23, 2023 ("The Reorganization"). The Reorganization involved the incorporation of Lakeside Holding Limited and the transfer the shares of American Bear Logistics Corp ("ABL Chicago") to the Company. Prior to the Reorganization, Mr. Henry Liu, the Chief Executive Officer ("CEO"), and Mr. Shuai Li, the President, each owned 50 % equity

View Full Filing

View this 10-Q filing on SEC EDGAR